IT201800005508A1 - Kit for use as a food supplement in the treatment of vitamin and / or mineral deficiencies in pediatrics. - Google Patents
Kit for use as a food supplement in the treatment of vitamin and / or mineral deficiencies in pediatrics. Download PDFInfo
- Publication number
- IT201800005508A1 IT201800005508A1 IT102018000005508A IT201800005508A IT201800005508A1 IT 201800005508 A1 IT201800005508 A1 IT 201800005508A1 IT 102018000005508 A IT102018000005508 A IT 102018000005508A IT 201800005508 A IT201800005508 A IT 201800005508A IT 201800005508 A1 IT201800005508 A1 IT 201800005508A1
- Authority
- IT
- Italy
- Prior art keywords
- concentration
- vitamin
- kit
- equal
- polysorbate
- Prior art date
Links
- 229940088594 vitamin Drugs 0.000 title claims description 38
- 229930003231 vitamin Natural products 0.000 title claims description 38
- 235000013343 vitamin Nutrition 0.000 title claims description 38
- 239000011782 vitamin Substances 0.000 title claims description 38
- 150000003722 vitamin derivatives Chemical class 0.000 title claims description 28
- 235000015872 dietary supplement Nutrition 0.000 title claims description 10
- 208000000412 Avitaminosis Diseases 0.000 title claims description 7
- 206010061291 Mineral deficiency Diseases 0.000 title claims description 6
- 206010047627 Vitamin deficiencies Diseases 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 claims description 41
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 21
- 239000011707 mineral Substances 0.000 claims description 21
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- 235000019155 vitamin A Nutrition 0.000 claims description 8
- 239000011719 vitamin A Substances 0.000 claims description 8
- 235000019166 vitamin D Nutrition 0.000 claims description 8
- 239000011710 vitamin D Substances 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 7
- 229910052804 chromium Inorganic materials 0.000 claims description 7
- 239000011651 chromium Substances 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- 229940068968 polysorbate 80 Drugs 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims description 6
- 239000011691 vitamin B1 Substances 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 229930003779 Vitamin B12 Natural products 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 229960003512 nicotinic acid Drugs 0.000 claims description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 229950008882 polysorbate Drugs 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 229960003495 thiamine Drugs 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 4
- 229930003451 Vitamin B1 Natural products 0.000 claims description 4
- 229940055726 pantothenic acid Drugs 0.000 claims description 4
- 235000019161 pantothenic acid Nutrition 0.000 claims description 4
- 239000011713 pantothenic acid Substances 0.000 claims description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- 239000002211 L-ascorbic acid Substances 0.000 claims description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 159000000014 iron salts Chemical class 0.000 claims description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 3
- 229960005055 sodium ascorbate Drugs 0.000 claims description 3
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 229920002642 Polysorbate 65 Polymers 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 claims description 2
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229940099511 polysorbate 65 Drugs 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 2
- 239000000047 product Substances 0.000 description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 208000018773 low birth weight Diseases 0.000 description 5
- 231100000533 low birth weight Toxicity 0.000 description 5
- 206010036590 Premature baby Diseases 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000006180 nutrition needs Nutrition 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940090568 combinations of vitamin Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
TITOLO: “Kit per uso come integratore alimentare nel trattamento delle carenze di vitamine e/o minerali in ambito pediatrico.” TITLE: "Kit for use as a food supplement in the treatment of vitamin and / or mineral deficiencies in the pediatric field."
DESCRIZIONE DESCRIPTION
CAMPO DELL’INVENZIONE FIELD OF THE INVENTION
La presente invenzione concerne un integratore alimentare, per uso pediatrico, per il trattamento di carenze vitaminiche o minerali. The present invention relates to a food supplement, for pediatric use, for the treatment of vitamin or mineral deficiencies.
STATO DELL’ARTE STATE OF THE ART
La carenza di vitamine è uno dei fattori di rischio per i soggetti in età pediatrica di incorrere in una maggiore incidenza di malattie stagionali e croniche. Vitamin deficiency is one of the risk factors for pediatric subjects to incur a higher incidence of seasonal and chronic diseases.
Tra i soggetti in età pediatrica, il neonato ed in particolar modo il prematuro, può avere una carenza di vitamine e/o minerali correlata ad un deficit di assunzione di tali nutrienti durante il periodo di gestazione. Among pediatric subjects, the newborn and especially the premature baby may have a deficiency of vitamins and / or minerals related to a deficit in the intake of these nutrients during the gestation period.
Per sopperire a tali mancanze, è possibile integrare la dieta del paziente mediante integratori alimentari a base di vitamine e minerali. To make up for these shortcomings, it is possible to supplement the patient's diet with food supplements based on vitamins and minerals.
Le formulazioni ad uso pediatrico disponibili in commercio sono preparate quasi esclusivamente in forma liquida, così da facilitare la somministrazione del prodotto anche al neonato, che ha diverse capacità di deglutizione rispetto all’adulto e che assume, quanto meno inizialmente, solo alimenti liquidi. The commercially available formulations for pediatric use are prepared almost exclusively in liquid form, so as to facilitate the administration of the product even to the newborn, who has different swallowing abilities compared to adults and who takes, at least initially, only liquid food.
Oltre che per la tipologia di formulazione farmaceutica, l’accettabilità delle preparazioni pediatriche in forma liquida dipende dal volume di liquido di somministrazione della dose utile, che dovrà essere il più contenuto possibile per garantire facilità di somministrazione e completa deglutizione da parte del paziente. In addition to the type of pharmaceutical formulation, the acceptability of pediatric preparations in liquid form depends on the volume of administration liquid of the useful dose, which must be as small as possible to ensure ease of administration and complete swallowing by the patient.
Il dosaggio degli attivi nei prodotti ad uso pediatrico si configura quindi come uno degli aspetti più critici della realizzazione di integratori alimentari multicomponente, che devono soddisfare sia i requisiti di compliance del paziente che di dosaggio efficace per unità di somministrazione. The dosage of the active ingredients in products for pediatric use is therefore one of the most critical aspects of the production of multi-component food supplements, which must satisfy both the patient's compliance requirements and effective dosage per administration unit.
Inoltre, la necessità di inserire molteplici attivi all'interno di un unico prodotto può causare problemi di stabilità del prodotto, soprattutto quando i componenti sono veicolati ad elevato contenuto, in un volume ridotto. Furthermore, the need to insert multiple active ingredients within a single product can cause problems of product stability, especially when the components are conveyed with a high content, in a small volume.
I prodotti disponibili in commercio propongono formulazioni contenenti combinazioni di vitamine o minerali che, per le difficoltà di inserimento dei nutrienti sopra menzionante, non coprono totalmente il fabbisogno del paziente in età pediatrica. The products available on the market offer formulations containing combinations of vitamins or minerals which, due to the difficulties in inserting the nutrients mentioned above, do not fully cover the needs of the pediatric patient.
Al fine di garantire un apporto completo di nutrienti al bambino, si ricorre allora alla combinazione di più integratori alimentari, con il rischio di sovra-dosaggio di alcuni attivi o sotto-dosaggio di altri. In order to ensure a complete supply of nutrients to the child, the combination of several food supplements is then used, with the risk of over-dosage of some active ingredients or under-dosage of others.
I supplementi a base di vitamine e minerali noti allo stato dell’arte inoltre, sono formulati in modo aspecifico per le esigenze del paziente, soprattutto perché non tengono conto della variabilità ad esempio tra il lattante, il neonato a termine ed il neonato prematuro, né tantomeno della variabilità soggettiva, in termini di peso corporeo, tra individuo ed individuo. Furthermore, the supplements based on vitamins and minerals known in the state of the art are formulated in a non-specific way for the needs of the patient, above all because they do not take into account the variability, for example, between the infant, the full term infant and the premature infant, nor let alone the subjective variability, in terms of body weight, between individual and individual.
È sentita l’esigenza di un prodotto specifico e modulabile, che contribuisca al benessere del soggetto in età pediatrica ed in particolare risponda alle esigenze nutrizionali del prematuro. The need is felt for a specific and modular product, which contributes to the well-being of the pediatric subject and in particular responds to the nutritional needs of the premature baby.
SOMMARIO DELL’INVENZIONE SUMMARY OF THE INVENTION
Per ovviare alle difficoltà tecniche di inserimento dei nutrienti, la Richiedente ha realizzato un kit comprendente due composizioni, una vitaminica ed una minerale, per uso come integratore alimentare in ambito pediatrico, e preferibilmente neonatale. To obviate the technical difficulties of nutrient insertion, the Applicant has made a kit comprising two compositions, one vitamin and one mineral, for use as a food supplement in the pediatric, and preferably neonatal, field.
La separazione degli attivi in due composizioni permette vantaggiosamente di veicolare ciascuna classe di attivi, vitamine e minerali, ad elevata concentrazione in un volume ridotto di prodotto, facilmente assumibile dal paziente. The separation of the active ingredients into two compositions advantageously allows to convey each class of active ingredients, vitamins and minerals, with a high concentration in a reduced volume of product, which can be easily taken by the patient.
La presenza di due composizioni separate permette altresì di modulare il dosaggio di assunzione, personalizzando la terapia di integrazione alimentare a seconda del soggetto in esame e tenendo conto della diversa natura delle due differenti carenze. The presence of two separate compositions also makes it possible to modulate the dosage of intake, customizing the dietary supplement therapy according to the subject under examination and taking into account the different nature of the two different deficiencies.
Oggetto della presente invenzione è un kit, per uso come integratore alimentare nel trattamento delle carenze di vitamine e/o minerali in soggetti in età pediatrica, comprendente The object of the present invention is a kit, for use as a food supplement in the treatment of vitamin and / or mineral deficiencies in pediatric subjects, comprising
a) una composizione vitaminica, in forma liquida, che contiene Vitamina C in concentrazione compresa tra 8% e 13% (g/mL); Vitamina E in concentrazione compresa tra 1,6% e 2,6% (g/mL); Niacina in concentrazione compresa tra 0,8% e 1,3% (g/mL); Vitamina B6 in concentrazione compresa tra 0,32% e 0,52% (g/mL); Acido Pantotenico in concentrazione compresa tra 0,32% e 0,52% (g/mL); Vitamina B2 in concentrazione compresa tra 0,16% e 0,26% (g/mL); Vitamina B1 in concentrazione compresa tra 0,16% e 0,26% (g/mL); Vitamina A in concentrazione compresa tra 0,096% e 0,156% (g/mL); Biotina in concentrazione compresa tra 0,016% e 0,026% (g/mL); Vitamina D in concentrazione compresa tra 0,002% e 0,0033% (g/mL); Vitamina B12 in concentrazione compresa tra 0,00032% e 0,00052% (g/mL), acido folico in concentrazione pari a 0,004% e 0,0065% (g/mL) in combinazione con adatti eccipienti e/o diluenti, e a) a vitamin composition, in liquid form, which contains Vitamin C in a concentration between 8% and 13% (g / mL); Vitamin E in a concentration between 1.6% and 2.6% (g / mL); Niacin in a concentration between 0.8% and 1.3% (g / mL); Vitamin B6 in a concentration between 0.32% and 0.52% (g / mL); Pantothenic acid in a concentration between 0.32% and 0.52% (g / mL); Vitamin B2 in a concentration between 0.16% and 0.26% (g / mL); Vitamin B1 in a concentration between 0.16% and 0.26% (g / mL); Vitamin A in a concentration between 0.096% and 0.156% (g / mL); Biotin in a concentration between 0.016% and 0.026% (g / mL); Vitamin D in a concentration between 0.002% and 0.0033% (g / mL); Vitamin B12 in concentrations between 0.00032% and 0.00052% (g / mL), folic acid in concentrations of 0.004% and 0.0065% (g / mL) in combination with suitable excipients and / or diluents, and
b) una composizione minerale, in forma liquida, che contiene Ferro in concentrazione compresa tra 0,48% e 0,72% (g/mL); Zinco in concentrazione compresa tra 0,4% e 0,6% (g/mL); Rame in concentrazione compresa tra 0,16% e 0,24% (g/mL); Iodio in concentrazione compresa tra 0,004% e 0,006% (g/mL), Selenio in concentrazione compresa tra 0,00016% e 0,00024% (g/mL), Cromo in concentrazione compresa tra 0,0008% e 0,0012% (g/mL), in combinazione con adatti eccipienti e/o diluenti. b) a mineral composition, in liquid form, which contains Iron in a concentration between 0.48% and 0.72% (g / mL); Zinc in a concentration between 0.4% and 0.6% (g / mL); Copper in a concentration between 0.16% and 0.24% (g / mL); Iodine in a concentration between 0.004% and 0.006% (g / mL), Selenium in a concentration between 0.00016% and 0.00024% (g / mL), Chromium in a concentration between 0.0008% and 0.0012% (g / mL), in combination with suitable excipients and / or diluents.
DESCRIZIONE DETTAGLIATA DELL’INVENZIONE DETAILED DESCRIPTION OF THE INVENTION
Negli scopi della presente invenzione, per soggetto in età pediatrica si intende un bambino avente da 0 a 18 anni di età, dove il soggetto avente da 0 fino a 28 giorni di vita è denominato neonato. For the purposes of the present invention, by pediatric subject is meant a child having from 0 to 18 years of age, where the subject having from 0 to 28 days of life is called a newborn.
Preferibilmente, per soggetto in età pediatrica si intende il bambino di età compresa tra 0 e 10 anni. Preferably, by pediatric subject we mean the child aged between 0 and 10 years.
Più preferibilmente, per soggetto in età pediatrica si intende il bambino di età compresa tra 0 e 6 anni. More preferably, by pediatric subject is meant the child aged between 0 and 6 years.
Si noti che per neonato si intende il neonato a termine, il neonato pretermine ed il neonato con peso corporeo alla nascita inferiore a 2500 g. Note that the term neonate refers to the term infant, the preterm infant and the infant with a body weight at birth of less than 2500 g.
Secondo la forma di realizzazione preferita, il kit oggetto della presente invenzione è destinato al trattamento delle carenze di vitamine e/o minerali nel neonato. According to the preferred embodiment, the kit object of the present invention is intended for the treatment of vitamin and / or mineral deficiencies in the newborn.
Il neonato si definisce “pretermine” se nasce prima di aver completato la 37<a >settimana di gestazione, cioè, prima che siano trascorsi 259 giorni dall’ultima mestruazione materna. The newborn is defined as "preterm" if it is born before completing the 37 <a> week of gestation, that is, before 259 days have elapsed since the last maternal menstruation.
Il neonato è invece “a termine” se nasce tra la 37<a >e la 42<a >settimana di gravidanza. The newborn is instead "full term" if it is born between 37 <a> and 42 <a> week of pregnancy.
Se si considera il peso alla nascita (PN) del neonato prematuro, si parla di: If we consider the birth weight (PN) of the premature baby, we talk about:
Neonato di basso peso (LBW: Low Birth Weight) se PN < 2500 g; Low birth weight infant (LBW: Low Birth Weight) if PN <2500 g;
Neonato di peso molto basso (VLBW: Very Low Birth Weight) se PN < 1500 g; e Very Low Birth Weight (VLBW) if PN <1500 g; And
Neonato di peso estremamente basso (VVLBW: Very Very Low Birth Weight o ELBW: Extremely Low Birth Weight) se PN < 1000 g (http://www.ospedalebambinogesu.it/neonato-pretermine#.Wv0xt4iFNPY). Extremely low weight infant (VVLBW: Very Very Low Birth Weight or ELBW: Extremely Low Birth Weight) if PN <1000 g (http://www.ospedalebambinogesu.it/neonato-pretermine#.Wv0xt4iFNPY).
Le vitamine possiedono un ruolo estremamente importante nello sviluppo del bambino in età pediatrica, soprattutto nelle prime fasi della crescita: necessarie in minime quantità per i fabbisogni dell’organismo, le vitamine regolano una serie di funzioni metaboliche ed energetiche, spesso in qualità di cofattori enzimatici. Vitamins play an extremely important role in the development of the child in pediatric age, especially in the early stages of growth: necessary in minimal quantities for the body's needs, vitamins regulate a series of metabolic and energy functions, often acting as enzymatic cofactors .
In base alla solubilità, le Vitamine si distinguono in Idrosolubili, comprendenti le vitamine B1(tiamina), B2 (riboflavina), B5, B6, B12, B3 (niacina, nicotinnamide o vitamina PP), acido folico, vitamina H, C; e Liposolubili, comprendenti le vitamine A, D, E, K. Based on solubility, Vitamins are divided into Water-soluble, including vitamins B1 (thiamine), B2 (riboflavin), B5, B6, B12, B3 (niacin, nicotinnamide or vitamin PP), folic acid, vitamin H, C; and Fat-soluble, including vitamins A, D, E, K.
In particolare, nei bambini prematuri, è indicata la supplementazione delle vitamine D, E, K e B6, dell’acido folico e l’integrazione della vitamina A, che sembra prevenire complicanze polmonari. In particular, in premature babies, the supplementation of vitamins D, E, K and B6, folic acid and the integration of vitamin A is indicated, which seems to prevent pulmonary complications.
Secondo una forma di realizzazione alternativa, la composizione vitaminica del kit secondo la presente invenzione può eventualmente contenere anche Vitamina K. According to an alternative embodiment, the vitamin composition of the kit according to the present invention may optionally also contain Vitamin K.
Un deficit di Vitamina K nei neonati può comportare un piccolo ma reale rischio di morte o di danni permanenti al cervello, a causa di emorragie, in particolar modo nei primi sei mesi di vita. Vitamin K deficiency in infants can carry a small but real risk of death or permanent brain damage from bleeding, particularly in the first six months of life.
Le Vitamine B1, B2, B3, B12 e C contribuiscono al normale funzionamento del sistema nervoso. La Vitamina B2 inoltre protegge le cellule dallo stress ossidativo e contribuisce al mantenimento della capacità visiva normale. Vitamins B1, B2, B3, B12 and C contribute to the normal functioning of the nervous system. Vitamin B2 also protects cells from oxidative stress and contributes to the maintenance of normal vision.
L’acido folico (Vitamina B9) e la Vitamina B12 contribuiscono al normale funzionamento del sistema immunitario ed all’emopoiesi. Folic acid (Vitamin B9) and Vitamin B12 contribute to the normal functioning of the immune system and hematopoiesis.
La Vitamina C contribuisce al normale funzionamento del sistema nervoso ed immunitario, all’assorbimento del ferro. Insieme alla Vitamina E, la Vitamina C protegge le cellule dagli stress ossidativi. Vitamin C contributes to the normal functioning of the nervous and immune systems, to the absorption of iron. Together with Vitamin E, Vitamin C protects cells from oxidative stress.
La Vitamina D promuove la mineralizzazione ossea, aumentando l’assorbimento di calcio e fosforo nell’intestino. Vitamin D promotes bone mineralization by increasing the absorption of calcium and phosphorus in the intestine.
La biotina (vitamina H) è coinvolta in reazione di carbossilazione. La biotina contribuisce al normale metabolismo energetico, al normale funzionamento del sistema nervoso e al normale metabolismo dei macronutrienti (https://www.dupitalia.com/portfolio/previtamin-gocce/). Biotin (vitamin H) is involved in the carboxylation reaction. Biotin contributes to normal energy metabolism, to the normal functioning of the nervous system and to the normal metabolism of macronutrients (https://www.dupitalia.com/portfolio/previtamin-gocce/).
La composizione vitaminica del kit secondo l’invenzione comprende preferibilmente almeno un polisorbato scelto dal gruppo costituito da: polisorbato 20, polisorbato 40, polisorbato 60, polisorbato 65 e polisorbato 80. The vitamin composition of the kit according to the invention preferably comprises at least one polysorbate selected from the group consisting of: polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65 and polysorbate 80.
Si noti che, secondo la forma di realizzazione preferita, detto almeno un polisorbato è il polisorbato 80. It should be noted that, according to the preferred embodiment, said at least one polysorbate is polysorbate 80.
La composizione vitaminica del kit comprende polisorbato 80 preferibilmente in concentrazione compresa tra 0,32% - 0,48% in peso sul peso della composizione vitaminica. The vitamin composition of the kit comprises polysorbate 80 preferably in a concentration comprised between 0.32% - 0.48% by weight on the weight of the vitamin composition.
Il polisorbato, quale eccipiente, ha una funzione emulsionante e stabilizzante, che permette la corretta dispersione delle vitamine liposolubili in mezzo acquoso. The polysorbate, as an excipient, has an emulsifying and stabilizing function, which allows the correct dispersion of the fat-soluble vitamins in an aqueous medium.
La composizione vitaminica comprende preferibilmente Vitamina C in forma di sodio ascorbato ed acido L-ascorbico in rapporto ponderale pari a 2,5 – 1. The vitamin composition preferably comprises Vitamin C in the form of sodium ascorbate and L-ascorbic acid in a weight ratio equal to 2.5 - 1.
L’impiego di una combinazione di acido L-ascorbico e sodio ascorbato, permette vantaggiosamente di modulare il pH finale del preparato all’interno di un intervallo che influisce limitatamente sulla solubilità degli altri componenti. Nel complesso questo conferisce al prodotto caratteristiche tali da renderlo dosabile in gocce. The use of a combination of L-ascorbic acid and sodium ascorbate advantageously allows to modulate the final pH of the preparation within a range that has a limited effect on the solubility of the other components. Overall this gives the product characteristics such as to make it dosable in drops.
Anche i minerali ricoprono un ruolo importante nella crescita del neonato: Zinco, Rame e Selenio sono coinvolti nella differenziazione cellulare, nello sviluppo e maturazione del sistema immunitario e nella protezione cellulare dagli stress ossidativi. Minerals also play an important role in the growth of the newborn: Zinc, Copper and Selenium are involved in cell differentiation, in the development and maturation of the immune system and in cellular protection from oxidative stress.
Il Ferro è un componente importante dell'emoglobina, una sostanza presente nei globuli rossi e che ha la funzione di trasportare l'ossigeno a tutti i tessuti. La quantità di ferro è proporzionale alla durata della gravidanza e pertanto il bambino che nasce prematuro, se non adeguatamente trattato, andrà certamente incontro ad uno stato di carenza (http://www.mammaepapa.it/neonato/p.asp?nfile=ferro_neonato). Iron is an important component of hemoglobin, a substance present in red blood cells and which has the function of transporting oxygen to all tissues. The amount of iron is proportional to the duration of pregnancy and therefore the baby who is born prematurely, if not adequately treated, will certainly face a state of deficiency (http://www.mammaepapa.it/neonato/p.asp?nfile= ferro_neonato).
Lo iodio è indispensabile per il buon funzionamento della tiroide in quanto rappresenta il costituente principale degli ormoni tiroidei T3 e T4. Limitate quantità di iodio durante lo sviluppo fetale o neonatale possono portare, nei casi più gravi, a danni per il cervello e per tutto il sistema nervoso centrale e, di conseguenza, a un ritardo mentale o a deficit intellettivi minori (http://www.epicentro.iss.it/problemi/iodio/iodio.asp). Iodine is essential for the proper functioning of the thyroid as it is the main constituent of the thyroid hormones T3 and T4. Limited quantities of iodine during fetal or neonatal development can lead, in severe cases, to damage to the brain and to the entire central nervous system and, consequently, to mental retardation or minor intellectual deficits (http: // www. epicentro.iss.it/problemi/iodio/iodio.asp).
Il cromo interviene nel metabolismo degli zuccheri, dei grassi e delle proteine. Il neonato prematuro nutrito per via parenterale può essere soggetto a fenomeni di iperglicemia precoce. In questi casi il cromo può essere di aiuto, in quanto migliora la tolleranza al glucosio potenziando l’azione dell’insulina (Kristin Capone MD, Sudhir Sriram MD, Tiffany Patton MD, Dana Weinstein RD, Ellen Newton RN Kristen Wroblewski MS, Timothy Sentongo MD, Clinical Research - Effects of Chromium on Glucose Tolerance in Infants Receiving Parenteral Nutrition Therapy, Nutrition in Clinical Practice, First published: 14 December 2017 https://doi.org/10.1177/0884533617711162). Chromium is involved in the metabolism of sugars, fats and proteins. The premature infant who is parenterally fed may be subject to early hyperglycemia. In these cases, chromium can help, as it improves glucose tolerance by enhancing the action of insulin (Kristin Capone MD, Sudhir Sriram MD, Tiffany Patton MD, Dana Weinstein RD, Ellen Newton RN Kristen Wroblewski MS, Timothy Sentongo MD, Clinical Research - Effects of Chromium on Glucose Tolerance in Infants Receiving Parenteral Nutrition Therapy, Nutrition in Clinical Practice, First published: 14 December 2017 https://doi.org/10.1177/0884533617711162).
La composizione vitaminica e la composizione minerale sono preferibilmente in forma di soluzione, erogabile in gocce. The vitamin composition and the mineral composition are preferably in the form of a solution, dispensable in drops.
Secondo la forma di realizzazione preferita, il dosaggio giornaliero della composizione vitaminica è almeno pari a 12 gocce (0,5 mL), mentre il dosaggio giornaliero della composizione minerale è preferibilmente almeno pari a 9 gocce (0,5 mL). According to the preferred embodiment, the daily dosage of the vitamin composition is at least equal to 12 drops (0.5 mL), while the daily dosage of the mineral composition is preferably at least equal to 9 drops (0.5 mL).
Si noti che, secondo la forma di realizzazione più preferita, il kit secondo l’invenzione comprende: Note that, according to the most preferred embodiment, the kit according to the invention comprises:
a) una composizione vitaminica, in forma liquida, che contiene Vitamina C in concentrazione pari a 10% (g/mL); Vitamina E in concentrazione pari a 2,0% (g/mL); Niacina in concentrazione pari 1,0% (g/mL); Vitamina B6 in concentrazione pari a 0,40% (g/mL); Acido Pantotenico in concentrazione pari a 0,40% (g/mL); Vitamina B2 in concentrazione pari a 0,20% (g/mL); Vitamina B1 in concentrazione pari a 0,20% (g/mL); Vitamina A in concentrazione pari a 0,12% (g/mL); Biotina in concentrazione pari a 0,020% (g/mL); Vitamina D in concentrazione pari a 0,0025% (g/mL); Vitamina B12 in concentrazione pari a 0,00040% (g/mL), acido folico in concentrazione pari a 0,005% in combinazione con adatti eccipienti e/o diluenti, a) a vitamin composition, in liquid form, which contains Vitamin C in a concentration equal to 10% (g / mL); Vitamin E in a concentration equal to 2.0% (g / mL); Niacin in a concentration of 1.0% (g / mL); Vitamin B6 in a concentration equal to 0.40% (g / mL); Pantothenic acid in a concentration of 0.40% (g / mL); Vitamin B2 in a concentration of 0.20% (g / mL); Vitamin B1 in a concentration of 0.20% (g / mL); Vitamin A in a concentration of 0.12% (g / mL); Biotin in a concentration of 0.020% (g / mL); Vitamin D in a concentration equal to 0.0025% (g / mL); Vitamin B12 in a concentration of 0.00040% (g / mL), folic acid in a concentration of 0.005% in combination with suitable excipients and / or diluents,
b) una composizione minerale, in forma liquida, che contiene sali farmaceuticamente accettabili di Ferro in concentrazione pari a 0,60% (g/mL); Zinco in concentrazione pari a 0,5% (g/mL); Rame in concentrazione pari a 0,20% (g/mL); Iodio in concentrazione pari a 0,005% (g/mL), Selenio in concentrazione pari a 0,00020% (g/mL), Cromo in concentrazione pari a 0,0010% (g/mL), in combinazione con adatti eccipienti e/o diluenti. b) a mineral composition, in liquid form, which contains pharmaceutically acceptable iron salts in a concentration equal to 0.60% (g / mL); Zinc in a concentration equal to 0.5% (g / mL); Copper in a concentration of 0.20% (g / mL); Iodine in a concentration equal to 0.005% (g / mL), Selenium in a concentration equal to 0.00020% (g / mL), Chromium in a concentration equal to 0.0010% (g / mL), in combination with suitable excipients and / or thinners.
Si noti che la concentrazione espressa in percentuale g/mL si riferisce al peso in g dell’attivo sul volume in mL della soluzione della composizione a) o della composizione b). Note that the concentration expressed as a percentage g / mL refers to the weight in g of the active on the volume in mL of the solution of composition a) or composition b).
Eccipienti e/o diluenti della composizione vitaminica e di quella minerale sono preferibilmente scelti tra uno o più dei seguenti: Excipients and / or diluents of the vitamin and mineral composition are preferably selected from one or more of the following:
Acqua, quale diluente degli attivi vitaminici e minerali; Fruttosio, quale dolcificante e addensante, conferisce al prodotto caratteristiche di densità che favoriscono l’omogeneità dello stesso; Gomma di xanthan, quale addensante, coadiuva e completa l’azione del fruttosio nel conferire al prodotto caratteristiche di densità tali da migliorare l’omogeneità dei componenti; Sucralosio, quale dolcificante, per migliorare la palatabilità delle composizioni; Acido citrico, come correttore di pH, per l’attivazione del Potassio sorbato, impiegato quale conservante. Water, as a diluent of the vitamin and mineral active ingredients; Fructose, as a sweetener and thickener, gives the product density characteristics that favor its homogeneity; Xanthan gum, as a thickener, assists and completes the action of fructose in giving the product characteristics of density such as to improve the homogeneity of the components; Sucralose, as a sweetener, to improve the palatability of the compositions; Citric acid, as a pH corrector, for the activation of potassium sorbate, used as a preservative.
Vantaggiosamente, le composizioni del kit oggetto dell’invenzione possono essere dosate sia in gocce che in mL. Advantageously, the compositions of the kit object of the invention can be dosed both in drops and in mL.
L’associazione di due composizioni permette di superare il limite tecnologico dell’associazione di sali e vitamine in certe concentrazioni, altrimenti incompatibili in unico prodotto a causa delle caratteristiche di solubilità dei componenti. Allo stesso tempo il prodotto, nel suo complesso, risulta completo per l’apporto della componente di vitamine e minerali. The combination of two compositions allows to overcome the technological limit of the association of salts and vitamins in certain concentrations, otherwise incompatible in a single product due to the solubility characteristics of the components. At the same time, the product as a whole is complete due to the contribution of the vitamin and mineral component.
Il dosaggio di ciascuna composizione può essere modulato indipendentemente dal dosaggio dell’altra, così da poter realizzare, per ogni soggetto, un trattamento ad hoc sulla base delle esigenze nutrizionali del paziente. The dosage of each composition can be modulated independently of the dosage of the other, so as to be able to create, for each subject, an ad hoc treatment based on the nutritional needs of the patient.
ESEMPI EXAMPLES
Si riporta di seguito, a scopo illustrativo e non limitativo, un esempio della composizione del kit oggetto della presente invenzione. An example of the composition of the kit object of the present invention is given below, for illustrative and non-limiting purposes.
Composizione Minerale: Flacone da 15 mL Mineral composition: 15 mL bottle
Composizione Vitaminica: Flacone da 15 mL Vitamin Composition: 15 mL bottle
% VNR = percentuale del valore nutritivo di riferimento (Reg. UE n.1169/2011) % VNR = percentage of the reference nutritional value (Reg. UE n.1169 / 2011)
Metodo di preparazione della Composizione Vitaminica: Method of preparation of the Vitamin Composition:
L’allestimento del prodotto prevede l’unione di due fasi inizialmente separate. The preparation of the product involves the union of two initially separate phases.
La fase qui denominata fase 1 contiene tutte le vitamine fatta eccezione per le vitamine A, D ed E. Alla fase 1 vengono aggiunti il sistema conservante, i dolcificanti e gli addensati. The phase here called phase 1 contains all the vitamins except for vitamins A, D and E. The preservative system, sweeteners and thickeners are added to phase 1.
La fase 2 è costituita da Vitamine A, D, E e polisorbato 80, miscelati fino ad ottenimento di un liquido omogeneo. Phase 2 consists of Vitamins A, D, E and polysorbate 80, mixed until a homogeneous liquid is obtained.
La fase 2 viene infine versata sulla Fase 1 lentamente, assicurando la corretta miscelazione di una fase con l’altra. Phase 2 is finally poured onto Phase 1 slowly, ensuring the correct mixing of one phase with the other.
Metodo di preparazione della Composizione Minerale: Method of preparation of the mineral composition:
L’allestimento del prodotto prevede un’unica fase in cui vengono inseriti dapprima i Sali minerali, seguiti, in un secondo momento, da sistema conservante, dolcificanti e addensanti. The preparation of the product involves a single phase in which the mineral salts are first inserted, followed, at a later time, by a preservative system, sweeteners and thickeners.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102018000005508A IT201800005508A1 (en) | 2018-05-18 | 2018-05-18 | Kit for use as a food supplement in the treatment of vitamin and / or mineral deficiencies in pediatrics. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102018000005508A IT201800005508A1 (en) | 2018-05-18 | 2018-05-18 | Kit for use as a food supplement in the treatment of vitamin and / or mineral deficiencies in pediatrics. |
Publications (1)
Publication Number | Publication Date |
---|---|
IT201800005508A1 true IT201800005508A1 (en) | 2019-11-18 |
Family
ID=63449527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT102018000005508A IT201800005508A1 (en) | 2018-05-18 | 2018-05-18 | Kit for use as a food supplement in the treatment of vitamin and / or mineral deficiencies in pediatrics. |
Country Status (1)
Country | Link |
---|---|
IT (1) | IT201800005508A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2347662A2 (en) * | 2008-11-13 | 2011-07-27 | Comercializadora S. Car Borr, S.A. de C.V. | Kit of pharmaceutical formulations characterised by the presence of molecular oxygen |
WO2014049566A2 (en) * | 2012-09-28 | 2014-04-03 | Stellenbosch University | Nutritional kit |
WO2014155370A1 (en) * | 2013-03-29 | 2014-10-02 | Omega Pharma Innovation & Development Nv | Kit with multiple nutritional supplements and a method for assembling thereof |
WO2016149655A1 (en) * | 2015-03-18 | 2016-09-22 | Callion Pharma, Llc | Scalable vitamin composition unit dosage for the treatment of fat-soluble vitamin deficiencies |
-
2018
- 2018-05-18 IT IT102018000005508A patent/IT201800005508A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2347662A2 (en) * | 2008-11-13 | 2011-07-27 | Comercializadora S. Car Borr, S.A. de C.V. | Kit of pharmaceutical formulations characterised by the presence of molecular oxygen |
WO2014049566A2 (en) * | 2012-09-28 | 2014-04-03 | Stellenbosch University | Nutritional kit |
WO2014155370A1 (en) * | 2013-03-29 | 2014-10-02 | Omega Pharma Innovation & Development Nv | Kit with multiple nutritional supplements and a method for assembling thereof |
WO2016149655A1 (en) * | 2015-03-18 | 2016-09-22 | Callion Pharma, Llc | Scalable vitamin composition unit dosage for the treatment of fat-soluble vitamin deficiencies |
Non-Patent Citations (2)
Title |
---|
DATABASE GNPD [online] MINTEL; 18 June 2018 (2018-06-18), ANONYMOUS: "Orange Flavoured Dietary Supplement Syrup", XP055518587, retrieved from www.gnpd.com Database accession no. 5743059 * |
DATABASE GNPD [online] MINTEL; 25 May 2007 (2007-05-25), ANONYMOUS: "Multivitamin & Mineral Complex", XP055518595, retrieved from www.gnpd.com Database accession no. 710817 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vanek et al. | ASPEN position paper: recommendations for changes in commercially available parenteral multivitamin and multi–trace element products | |
Sandström et al. | Effects of α-lactalbumin–enriched formula containing different concentrations of glycomacropeptide on infant nutrition | |
RU2586928C2 (en) | Modulation of growth of bifidus bacteria in combination with oligosaccharides in breast milk | |
RU2555584C2 (en) | Milk mixture for premature babies | |
US5340603A (en) | Nutritional product for human infants having chronic lung disease | |
WO2013174306A1 (en) | Infant formula milk powder and preparation method thereof | |
MXPA05003088A (en) | Leucine-enriched nutritional compositions. | |
JPH04346770A (en) | Nutrition supply composition | |
JP2012197293A (en) | Total enteral nutritious composition | |
US10064835B2 (en) | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers | |
Salle et al. | Effects of calcium and phosphorus supplementation on calcium retention and fat absorption in preterm infants fed pooled human milk | |
EP1549158B1 (en) | Infant formula containing nucleotides | |
Sandoval et al. | Trends in diagnosis and management of iron deficiency during infancy and early childhood | |
Schanler | The low birth weight infant | |
Anderson et al. | Mineral and vitamin status on high-fiber diets: long-term studies of diabetic patients | |
Shakiba et al. | Combination of bolus dose vitamin D with routine vaccination in infants: a randomised trial. | |
Hanning et al. | Efficacy of calcium glycerophosphate vs conventional mineral salts for total parenteral nutrition in low-birth-weight infants: a randomized clinical trial | |
TW201332555A (en) | Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring | |
EP1108429A2 (en) | An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases | |
CN106604651A (en) | Nutritional composition for treating or preventing pregnancy-related disorders | |
CN104379172B (en) | Nutritional composition | |
IT201800005508A1 (en) | Kit for use as a food supplement in the treatment of vitamin and / or mineral deficiencies in pediatrics. | |
KR101465554B1 (en) | A functional food composition for triglyceride in blood and reducing inflammation level containing Methyl Sulfonyl Methane | |
Lee et al. | Implementation of nutrition practice improves growth velocity and weight gain in premature infants≤ 1250 grams | |
Leaf et al. | Vitamins for preterm infants |